Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group.

J Hepatol. 2013 Jun;58(6):1104-12. doi: 10.1016/j.jhep.2013.01.042. Epub 2013 Feb 7.

PMID:
23395690
2.

Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.

Berenguer J, Zamora FX, Carrero A, Von Wichmann MA, Crespo M, López-Aldeguer J, Aldámiz-Echevarría T, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Esteban H, Bellón JM, González-García J; GESIDA HIVHCV Cohort Study Group.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):280-7. doi: 10.1097/QAI.0000000000000156.

PMID:
25157646
3.

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.

Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group.

Hepatology. 2009 Aug;50(2):407-13. doi: 10.1002/hep.23020.

PMID:
19575364
4.

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group.

Clin Infect Dis. 2012 Sep;55(5):728-36. Epub 2012 May 18.

5.

Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.

Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, López-Aldeguer J, Alvarez-Pellicer J, De Miguel J, Crespo M, Guardiola JM, Tellez MJ, Galindo MJ, Arponen S, Barquilla E, Bellón JM, González-García J; GESIDA 36/03 and 50/06 Study Groups.

J Antimicrob Chemother. 2011 Dec;66(12):2843-9. doi: 10.1093/jac/dkr362. Epub 2011 Sep 29.

6.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

7.

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Soriano V, Maida I, Núñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, González-Lahoz J.

Antivir Ther. 2004 Dec;9(6):987-92.

PMID:
15651757
8.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1. doi: 10.1016/j.cgh.2011.03.004. Epub 2011 Mar 11.

PMID:
21397729
9.

Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.

Mancuso ME, Rumi MG, Aghemo A, Santagostino E, Puoti M, Coppola A, Colombo M, Mannucci PM.

J Thromb Haemost. 2009 Dec;7(12):1997-2005. doi: 10.1111/j.1538-7836.2009.03624.x. Epub 2009 Oct 3.

10.

Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.

Bani-Sadr F, Krastinova E, Fromentin D, Piroth L, Rosenthal E, Quertainmont Y, Perronne C, Cacoub P, Pol S, Carrat F; ANRS CO 07-Ribavic Study team.

J Viral Hepat. 2012 Jun;19(6):431-5. doi: 10.1111/j.1365-2893.2011.01570.x. Epub 2012 Jan 4.

PMID:
22571905
11.

Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.

Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, Tincati C, Borghi F, Carosi G, Puoti M, Monforte Ad.

PLoS One. 2012;7(2):e32028. doi: 10.1371/journal.pone.0032028. Epub 2012 Feb 21.

12.

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Moreno L, Quereda C, Moreno A, Perez-Elías MJ, Antela A, Casado JL, Dronda F, Mateos ML, Bárcena R, Moreno S.

AIDS. 2004 Jan 2;18(1):67-73.

PMID:
15090831
13.

Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V.

J Viral Hepat. 2008 Oct;15(10):710-5. doi: 10.1111/j.1365-2893.2008.01015.x. Epub 2008 Jul 10.

PMID:
18637070
14.

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.

Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.

Ann Hepatol. 2013 Mar-Apr;12(2):228-35.

15.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

AIDS. 2008 Jan 2;22(1):15-21.

PMID:
18090387
16.

Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.

Piedoux S, Monnet E, Piroth L, Montange D, Royer B, Thevenot T, Kantelip JP, Di Martino V, Muret P; RibAct group.

Antivir Ther. 2011;16(8):1317-26. doi: 10.3851/IMP1920.

PMID:
22155913
17.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
18.
19.

Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon.

Ferreira Sda C, Carneiro Mde V, Souza FF, Teixeira AC, Villanova MG, Figueiredo JF, Passos AD, Ramalho LN, Zucoloto S, Martinelli Ade L.

Braz J Infect Dis. 2010 Jul-Aug;14(4):330-4.

20.

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.

Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A.

AIDS. 2007 Feb 19;21(4):477-81.

PMID:
17301566
Items per page

Supplemental Content

Write to the Help Desk